cefaclor
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
143
Go to page
1
2
3
4
5
6
November 24, 2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
(PubMed, J Antimicrob Chemother)
- "Pneumococci were susceptible to fluoroquinolones (>98%), amoxicillin and amoxicillin/clavulanic acid (>79%-94%), ceftriaxone and cefotaxime (>73%-94%). Susceptibility was lower to oral/low-dose penicillin (20%-27%), macrolides (33%-51%), tetracyclines (53%-59%) and trimethoprim/sulfamethoxazole (33%-61%). Susceptibility was generally >80% in H. influenzae except for trimethoprim/sulfamethoxazole (47%-56%)."
Journal • PK/PD data • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases
November 24, 2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
(PubMed, J Antimicrob Chemother)
- "Although antimicrobial resistance was observed, many therapeutic options remain to treat S. pneumoniae and H. influenzae from CA-RTI in Pakistan despite concerns about high levels of inappropriate antibiotic use. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs."
Journal • PK/PD data • Infectious Disease • Influenza • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases
November 24, 2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
(PubMed, J Antimicrob Chemother)
- "For H. influenzae, 100% susceptibility (CLSI) was observed to amoxicillin/clavulanic acid, macrolides, most cephalosporins and tetracycline. S. pneumoniae susceptibility was 100% to fluoroquinolones, 90.6%-96.9% to third-generation cephalosporins and 96.9% to amoxicillin and amoxicillin/clavulanic acid. This is consistent with previous resistance surveillance in Ukraine. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs."
Journal • PK/PD data • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases
November 24, 2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
(PubMed, J Antimicrob Chemother)
- "Susceptibility of S. pneumoniae to many antibiotics was low in both countries, with susceptibility > 90% observed only with high-dose penicillin and fluoroquinolones (CLSI and EUCAST) and high-dose amoxicillin or amoxicillin/clavulanic acid (PK/PD). Higher susceptibility was seen with H. influenzae in both countries. Continued surveillance of antimicrobial resistance is important for guiding therapy of CA-RTIs."
Journal • PK/PD data • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases
November 24, 2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
(PubMed, J Antimicrob Chemother)
- "Susceptibility in S. pneumoniae was 90% except for trimethoprim/sulfamethoxazole and ampicillin. These data are similar to recent surveillance of antibiotic resistance data in Türkiye."
Journal • PK/PD data • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases
November 15, 2025
Chemical instability of cefaclor in simple suspensions alkalinized with magnesium oxide and the structural elucidation of the degradation products.
(PubMed, J Pharm Sci)
- "The degradation products were isolated and spectroscopically identified to be piperazine derivatives including a novel one. Their plausible formation mechanisms have also been proposed."
Journal • Gastrointestinal Disorder • Infectious Disease
November 07, 2025
Unraveling the mechanisms behind the enhanced efficacy of β-lactam-based sideromycins.
(PubMed, Commun Biol)
- "This study evaluates three siderophore-β-lactam compounds: a bis-catechol siderophore linked to ampicillin or loracarbef, and a mixed bis-catechol-mono-hydroxamate siderophore linked to cefaclor. Enhanced PBP binding, particularly in Escherichia coli, emerged as a key factor contributing to improved bacterial inhibition by siderophore-β-lactam conjugates. Overall, the study provides insights into how siderophore conjugation enhances β-lactam activity and the therapeutic potential of the conjugates as narrow or broad-spectrum antibiotics."
Journal • Infectious Disease
November 06, 2025
A Case of Staphylococcus aureus Septic Arthritis After COVID-19 Vaccination.
(PubMed, J Gen Fam Med)
- "Intravenous administration of ceftriaxone was effective and de-escalated to cefazolin and then oral cefaclor. The patient was discharged without complications. Caution is warranted because unexpected complications may arise after vaccination in individuals with multiple comorbidities."
Journal • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Rheumatology
October 12, 2025
Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: age-stratified insights from the FAERS database.
(PubMed, J Pediatr (Rio J))
- "The study reveals clear age- and drug-specific patterns in pediatric SJS/TEN. Findings emphasize the importance of age-stratified pharmacovigilance issues and cautious prescribing of high-risk drugs such as lamotrigine and antibiotics. Better awareness of potential biases, such as protopathic misattribution, is crucial for accurate signal detection in pediatric pharmacovigilance."
Journal • Pediatrics • Steven-Johnson Syndrome
September 20, 2025
Identifying Genetic Variants in Patients With Cefaclor-Induced Anaphylaxis Using Human Leukocyte Antigen Typing and Whole-Exome Sequencing.
(PubMed, Clin Transl Allergy)
- "Genetic variants in TPSAB1 and HLA-DRB5 may contribute to the risk of cefaclor-induced anaphylaxis, and TPSAB1 may also be associated with severity. These findings may support the development of future screening strategies or individualized risk prediction models in β-lactam allergy."
Journal • Allergy • Hypotension • Immunology • HLA-DRB5 • TNFA • TPSAB1
September 16, 2025
Evaluation of Outpatient Antibiotic Use Using AWaRe and DDD/DOT Indicators: A Community Pharmacy-Based Study in Nayoro City, Japan.
(PubMed, J Infect Chemother)
- "This study identified regional overuse of Watch antibiotics and a shift toward Reserve agents during drug shortages. Hospital formulary restrictions likely influenced citywide prescribing trends. These findings highlight the need for stable antibiotic supply chains, formulary review, and locally adapted antimicrobial stewardship strategies."
Journal
July 19, 2025
Reevaluating the timing of specific immunoglobulin E measurement after anaphylaxis.
(PubMed, Allergol Immunopathol (Madr))
- "Here, we present a case of a patient with initial cefaclor-specific IgE negativity, but when tested immediately after confirmed anaphylaxis to cefaclor, the results converted to positive after the resolution of the anergic period, 8 weeks post reaction. In patients with a strong clinical suspicion of drug-induced anaphylaxis, repeating in vitro tests after the anergic period may be warranted, even if the initial results are negative. Further investigation is needed to assess whether ImmunoCAP values, similar to skin test reactivity, exhibit significant short-term variability."
Journal • Allergy • Immunology
June 25, 2025
In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic E. coli.
(PubMed, Antibiotics (Basel))
- " This study proposes a cost-effective combination that could mitigate resistance development and offer a sparing option to last resort treatment choices including carbapenems. However, testing efficacy in a clinical setting is crucial."
Journal • Preclinical • Infectious Disease • Nephrology
June 09, 2025
A critical role for Phocaeicola vulgatus in negatively impacting metformin response in diabetes.
(PubMed, Acta Pharm Sin B)
- "This work suggests that metformin may be unsuitable for P. vulgatus-rich T2DM patients and that clinicians should be aware of metformin toxicity to mitochondria. Suppressing P. vulgatus growth with cefaclor or improving mitochondrial function using adenosylcobalamin may represent simple, safe, effective therapeutic strategies for addressing MMF."
Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
May 06, 2025
DACAT: Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Allergy • Immunology
May 08, 2025
Simultaneous determination of cefmetazole and cefaclor in urine from pediatric patients with urinary tract infections using a newly developed high-performance liquid chromatography assay method.
(PubMed, Int J Clin Pharmacol Ther)
- "We developed and validated an HPLC-UV method for the simultaneous measurement of cefaclor and cefmetazole in pediatric patients with UTI. The assay is rapid, cost-effective, and suitable for therapeutic drug monitoring."
Journal • Infectious Disease • Nephrology • Pediatrics
April 27, 2025
Similarities in the consumption trajectory of antibacterial drugs in the outpatient care sector in Germany from 1986 to 2022: identification of shared patterns, correlation analysis of prescribed defined daily dose and assessment of underlying influences.
(PubMed, Naunyn Schmiedebergs Arch Pharmacol)
- "The first group, including doxycycline, phenoxymethylpenicillin and sulfamethoxazole-trimethoprim, showed declining trends with stable trajectories, its similarities being confirmed by overlapping indications such as respiratory tract infections and declining usage due to guideline changes. The second group, comprising amoxicillin-clavulanic acid, cefpodoxime and pivmecillinam, displayed increasing trends with continuous trajectories. The third group, including ciprofloxacin, clarithromycin and cefaclor, shared declining trends with fluctuating trajectories, often related to bacterial resistance rates and substitution by other antibacterial drugs...Distinguishing direct effects of changes in consumption from one drug to another from common but unrelated responses to external events remains a challenge, as there are many factors that can influence consumption. The findings provide a better understanding of the interdependencies in the consumption of the most commonly..."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 18, 2025
Genotyping and antimicrobial susceptibility of Aeromonas veronii isolated from aquatic animals in Sichuan, China.
(PubMed, Antonie Van Leeuwenhoek)
- "Discs of 17 antimicrobial agents were used, including penicillin, cefaclor, cefotaxime, meropenem, amoxicillin, kanamycin, gentamycin, amikacin, neomycin, ciprofloxacin, enrofloxacin, tetracycline, doxycycline, florfenicol, cotrimoxazole, rifampicin, and azithromycin. Our study indicated that different genotypes showed different distribution of ARPs and ARGs. To our knowledge, this is the first report of molecular subtyping and antibiotic resistance profiles in A. veronii from aquatic animals in Sichuan, these data provide a valuable referee for the prevention and control of corresponding diseases."
Journal
April 02, 2025
Clinical Observation on the Treatment of Acute Pharyngitis, Tonsillitis, Acute Exacerbation of Chronic Pharyngitis and Other Upper Respiratory Tract Infections Causing Throat Pain and Other Discomforts with Diquichloramine Lozenges: A Randomized Controlled Study
(ChiCTR)
- P4 | N=108 | Recruiting | Sponsor: Tianjin Fifth Central Hospital; Tianjin Fifth Central Hospital
New P4 trial • Infectious Disease • Otorhinolaryngology • Pain • Respiratory Diseases • CRP
April 03, 2025
Comparative evaluation of antimicrobial efficacy of 3C antibiotic paste with triple antibiotic paste as root canal filling material for primary teeth: An in-vitro study.
(PubMed, F1000Res)
- "Hence Triple Antibiotic Paste (TAP) has been previously introduced, consisting of ciprofloxacin, metronidazole, and minocycline...The aim of this study is to evaluate and compare the antimicrobial efficacy of a newly formulated 3C antibiotic paste (consisting of Ciprofloxacin, Clindamycin, and Cefaclor) with conventional TAP against E. faecalis and C. albicans...We hypothesise that the newly formulated 3C paste will have better antimicrobial efficacy when compared with conventional TAP. It is expected that a newly formulated 3C paste will prove to be the successful as root canal filling material for primary teeth."
Clinical • Journal • Preclinical • Gastrointestinal Disorder • Infectious Disease
March 28, 2025
Highlighting the Role of Prenatally Administered Drugs in the Production of Dental Enamel Defects in Rats by Polarized Light Microscopy.
(PubMed, Biomedicines)
- " In the control group, DDE was identified in a reduced number, resulting in the fact that there are other factors involved, besides the drugs administered, in the development of DDE. Following this research, it was concluded that DDE in the form of demineralization was more frequently recorded in the cefaclor and ibuprofen groups, while DDE in the form of hypoplasia was more frequently recorded in the double-dose and standard-dose amoxicillin groups."
Journal • Preclinical
March 10, 2025
Antimicrobial resistance and biofilm formation of penile prosthesis isolates: insights from in-vitro analysis.
(PubMed, J Sex Med)
- "Although increasing evidence supports the concept that all IPPs harbor biofilms, even in the absence of infection, a deeper understanding of the characteristics of bacteria that survive revisional surgery is warranted. This study demonstrated extensive biofilm forming capabilities, and resistance patterns among bacteria isolated from both non-infected and infected IPP revision surgeries. Further investigation is warranted to determine why some devices become infected while others remain colonized but non-infected."
Journal • Preclinical • Infectious Disease
March 05, 2025
Screening of cytokines-cytokine receptor-associated genes in childhood asthma based on bioinformatics.
(PubMed, Integr Biol (Camb))
- "We have determined that CCL26, CXCR6, IL18RAP and CCL20 might have crucial involvement in the advancement of childhood asthma, thus having the potential to be targeted therapeutically in order to enhance treatment choices for childhood asthma. Statement of Integration, Innovation and Insight: The cytokine-cytokine receptor interaction is a key pathway in the occurrence of childhood asthma. The hub genes (CCL26, CXCR6, IL18RAP and CCL20) affect the development of childhood asthma. The drugs (Cimetidine, Cefaclor and Propofol) that target hub genes have favorable combination ability."
Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CCL20 • CXCR6
March 04, 2025
Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation.
(PubMed, Biochem Biophys Rep)
- "Finally, we screened Celastrol and Cefaclor Anhydrous targeting IL1β as potent anti-inflammatory drug to reduce the inflammation due to TB. These findings were further validated with Molecular dynamic simulation MM-GBSA and PCA analysis. Our study advances the understanding of latent tuberculosis and identifies genes and microRNAs as potential biomarkers for diagnosis, monitoring, and treatment, with broader implications for complex disease research."
Journal • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL1B • TLR3
February 27, 2025
OraPAT-IEGAMES: Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
(clinicaltrials.gov)
- P4 | N=360 | Recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Jun 2024 ➔ Oct 2026
Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • CRP
1 to 25
Of
143
Go to page
1
2
3
4
5
6